Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2408399 | 0.90 | NPC1 (0.41) | SIGMAR1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL2406071 | 0.86 | SMN1; SMN2 (0.45) | SIGMAR1KDM4EALDH1A1KMT2A | |
| SCHEMBL12319348 | 0.85 | SMN1; SMN2 (0.38) | KDM4EALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL5380967 | 0.80 | SIGMAR1 (0.44) | SIGMAR1KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL1555898 | 0.80 | NPC1 (0.41) | SIGMAR1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL2408397 | 0.79 | TAAR1 (0.35) | CYP2D6 | |
| SCHEMBL13476066 | 0.74 | HPGD (0.49) | KDM4EALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL2408889 | 0.73 | HPGD (0.51) | KDM4EALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL12270487 | 0.73 | SSTR2 (0.43) | — | |
| SCHEMBL12270761 | 0.72 | LYPLA1 (0.48) | KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
| WO-2010018836-A2 | POLYGLUTAMINE AGGREGATION INHIBITOR | 独立行政法人科学技術振興機構 (JP) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010018837-A2 | PROTEIN CROSS-LINKING INHIBITOR | 独立行政法人科学技術振興機構 (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-7217701-B2 | Intracellular calcium concentration increase inhibitors | KATSUHIKO MIKOSHIBA (JP) | 2007-05-15 | — | — | US | disclosed |
| US-7217701-B2 | Intracellular calcium concentration increase inhibitors | KATSUHIKO MIKOSHIBA (JP) | 2007-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | BAZ2B, PRMT1, BRIX1 | SIGMAR1 2136/4885KDM4E 1022/4885ALDH1A1 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.